

09/744527

JC06 Rec'd

22 JAN 2001

PCX
BUXS

Date: January 22, 2001

Attorney Docket No. 45.US2.PCT

Page 1

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 USC 371**

International Application No.:
International Filing Date:
Priority Date Claimed:
Title of Invention:

PCT/IB99/01353

July 23, 1999

July 23, 1998

**A NUCLEIC ACID ENCODING A GERANYL-GERANYL-
PYROPHOSPHATE SYNTHASE (GGPPS) AND POLYMORPHIC
MARKERS ASSOCIATED WITH SAID NUCLEIC ACID.**

Lydie Bougueleret

Applicant(s) for DO/EO/US:

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. () This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. (X) A copy of the International Application as filed (35 USC 371(c)(2))
 - a) () is transmitted herewith (required only if not transmitted by the International Bureau).
 - b) (X) has been transmitted by the International Bureau.
 - c) () is not required, as the application was filed in the United States Receiving Office (RO/US).
6. () A translation of the International Application into English (35 USC 371(c)(2)).
7. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
 - a) () are transmitted herewith (required only if not transmitted by the International Bureau).
 - b) () have been transmitted by the International Bureau.
 - c) () have not been made; however, the time limit for making such amendments has NOT expired.
 - d) (X) have not been made and will not be made.
8. () A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. () An oath or declaration of the inventor(s) (35 USC 371(c)(4)).
10. (X) A copy of the International Preliminary Examination Report with any annexes thereto, such as any amendments made under PCT Article 34.
11. () A translation of the annexes, such as any amendments made under PCT Article 34, to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

09/744527-0500004

Date: January 22, 2001

Attorney Docket No.45.US2.PCT

Page 2

Items 12. to 23. below concern other document(s) r information included:

- 12. () An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 13. () An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 14. (X) A FIRST preliminary amendment.
() A SECOND or SUBSEQUENT preliminary amendment.
- 15. () A substitute specification.
- 16. () A power of attorney and/or address letter.
- 17. (X) International Application as published.
- 18. () Small Entity Statement.
- 19. (X) Sequence Submission Statement in 1 page.
- 20. (X) Paper Copy of the Sequence Listing in 13 pages.
- 21. (X) Sequence Listing in Computer Readable Format.
- 22. (X) A return prepaid postcard.
- 23. (X) The following fees are submitted:

				FEES
BASIC FEE				\$860.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	16 =	0 ×	\$18	\$0
Independent Claims	6 - 3 =	3 ×	\$80	\$240.00
Multiple dependent claims(s) (if applicable)			\$270	\$0
TOTAL OF ABOVE CALCULATIONS				\$1,100.00
Reduction by 1/2 for filing by small entity (if applicable). Verified Small Entity statement must also be filed. (NOTE 37 CFR 1.9, 1.27, 1.28)				\$0
TOTAL NATIONAL FEE				\$1,100.00
TOTAL FEES ENCLOSED				\$1,172.00
Please credit deposit account 501181:				\$72.000
amount to be charged:				\$0

- a. (X) A check in the amount of \$1172.00 to cover the above fees is enclosed.

09/744527-050001

Date: January 22, 2001

Attorney Docket No.45.US2.PCT

Page 3

- b. () Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property.
- c. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required, now or in the future, to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 501181. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GENSET CORPORATION
875Prospect Street, Suite 206
La Jolla CA 92037


Signature

22 JAN 01
John Lucas, Ph.D., J.D.
Registration No. 43,373

09/744527
500 Rec'd PCT/PTO 22 JAN 2001

09/744527

500 Rec'd PCT/PTO 22 JAN 2001

Assistant Commissioner for Patents
Washington, D.C. 20231


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Attorney Docket No. : 45.US2.PCT
Applicant(s) : Bougueleret, Lydie
For : A NUCLEIC ACID ENCODING A GERANYL-
GERANYL PYROPHOSPHATE SYNTHETASE
(GGPPS) AND POLYMORPHIC MARKERS
ASSOCIATED WITH SAID NUCLEIC ACID
Attorney : John Lucas
"Express Mail"
Mailing Label No. : EL549987818US
Date of Deposit : January 22, 2001

I hereby certify that the accompanying

Transmittal in 3 pages; International Application as published in 85 pages; International Preliminary Examination Report; FIRST Preliminary Amendment; Sequence Submission Statement in 1 page; Paper Copy of Sequence Listing in 13 pages; Sequence Listing in Computer Readable Format; A check in the amount of \$1172.00 to cover Filing Fee(s); Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Craig Worthem

EXPRESSMAILCERT